The Clorox Company CLX SPXR3K
Company Overview
The Clorox Company manufactures and markets consumer and professional products worldwide. The company operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers home care cleaning and disinfecting products, bleach, clog removers, and laundry additives under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr, Poett, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand in the United States. The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States. The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; water-filtration products under the Brita brand; and natural personal care products under the Burt's Bees brand in the United States. The International segment provides laundry additives, home care products, bags and wraps, cat litter products, water-filtration systems, professional cleaning and disinfecting products, natural personal care products, food, grilling products, and digestive health products internationally primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands. It also offers vitamins, minerals, and supplement products under the Natural Vitality, RenewLife, NeoCell, and Rainbow Light brands. The company sells its products through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet, and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force. The company was founded in 1913 and is headquartered in Oakland, California.
Why Investors Should Care
Operating margin of 16.4% supports profitability.
Offers a dividend yield of 4.73%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jun 2025 Revenue of $7.10B (+0.2% YoY); net profit $810.00M.
- Trailing 12 Months Year-on-year growth — revenue -2.0%, earnings -50.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.8%, profit CAGR 3.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.77% |
| 1 Year: | -2.00% |
Compounded Profit Growth
| 5 Years: | 3.37% |
| 1 Year: | -50.10% |
Stock Price Performance
| 1 Year: | -20.74% |
| 6 Months: | -16.86% |
| 3 Months: | +0.01% |
| 1 Month: | -10.85% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.48 · Neutral
P/E of 19.39 is above the sector median of 18.74 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 4.73%.
- Generates positive free cash flow.
CONS
- Trading 25.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLX The Clorox Company SPXR3K | 93.06 | 19.39 | $11.25B | 4.73% | - | - | 1.77% | 3.37% |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 37.73 | $852.63B | 0.88% | 16.83% | 24.13% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 915.74 | 46.16 | $406.11B | 0.62% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.07 | 26.45 | $378.93B | 2.44% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 146.44 | 22.32 | $341.00B | 2.96% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 182.53 | 25.07 | $284.49B | 3.13% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 137.63 | 18.04 | $188.00B | 4.28% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 80.35 | 17.32 | $140.40B | 1.61% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | MO Altria Group, Inc. SPXR3K | 68.88 | 14.50 | $115.01B | 6.26% | 38.27% | - | 1.24% | -1.89% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.52B | - | 1.56B | 1.47B | 1.55B | 1.63B | 1.51B | 1.45B | 1.78B | 1.98B | 1.92B | 1.84B | 1.78B | 1.80B | 1.81B | 1.69B | 1.81B | 1.74B | 1.72B | 1.92B | 1.39B | 1.99B | 1.81B | 1.76B | 1.69B | 1.67B | 1.43B | 1.67B | 1.67B |
| Gross Profit | - | 625.00M | 600.00M | 646.00M | - | 640.00M | 629.00M | 650.00M | - | 673.00M | 609.00M | 649.00M | - | 678.00M | 643.00M | 673.00M | - | 663.00M | 639.00M | 832.00M | - | 920.00M | 837.00M | 774.00M | - | 670.00M | 558.00M | 649.00M | 626.00M | 620.00M | 800.00M | 532.00M | 866.00M | 766.00M | 807.00M | 738.00M | 744.00M | 596.00M | 722.00M | 722.00M |
| Net Income | 191.00M | 172.00M | 149.00M | 162.00M | 165.00M | 179.00M | 149.00M | 172.00M | 201.00M | 192.00M | 233.00M | 181.00M | 217.00M | 210.00M | 182.00M | 187.00M | 241.00M | 203.00M | 185.00M | 241.00M | 310.00M | 415.00M | 259.00M | -61.00M | 97.00M | 142.00M | 69.00M | 150.00M | 85.00M | 99.00M | -211.00M | 22.00M | 93.00M | -51.00M | 99.00M | 193.00M | 186.00M | 80.00M | 157.00M | 187.00M |
| Diluted EPS | 1.46 | 1.31 | 1.13 | 1.23 | 1.26 | 1.36 | 1.14 | 1.31 | 1.52 | 1.46 | 1.77 | 1.37 | 1.66 | 1.62 | 1.40 | 1.44 | 1.88 | 1.59 | 1.46 | 1.89 | 2.41 | 3.22 | 2.03 | -0.49 | 0.78 | 1.14 | 0.56 | 1.21 | 0.68 | 0.80 | -1.71 | 0.17 | 0.75 | -0.41 | 0.80 | 1.54 | 1.50 | 0.65 | 1.29 | 1.54 |
| R&D Expense | - | 30.00M | 34.00M | 35.00M | - | 31.00M | 32.00M | 35.00M | - | 32.00M | 31.00M | 32.00M | - | 32.00M | 32.00M | 34.00M | - | 30.00M | 34.00M | 39.00M | - | 32.00M | 40.00M | 32.00M | - | 33.00M | 34.00M | 31.00M | 32.00M | 33.00M | 35.00M | 29.00M | 32.00M | 32.00M | 31.00M | 31.00M | 27.00M | 28.00M | 29.00M | 27.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.27B | 5.16B | 5.23B | 5.23B | 5.47B | 5.62B | 5.51B | 5.66B | 5.76B | 5.97B | 6.12B | 6.21B | 6.72B | 7.34B | 7.11B | 7.39B | 7.09B | 7.10B |
| Gross Profit | 2.17B | 2.20B | 2.32B | 2.27B | 2.30B | 2.39B | 2.36B | 2.46B | 2.60B | 2.67B | 2.67B | 2.73B | 3.06B | 3.20B | 2.54B | 2.91B | 3.05B | 3.21B |
| Net Income | 461.00M | 537.00M | 603.00M | 557.00M | 541.00M | 572.00M | 558.00M | 580.00M | 648.00M | 701.00M | 823.00M | 820.00M | 939.00M | 710.00M | 462.00M | 149.00M | 280.00M | 810.00M |
| Diluted EPS | 3.23 | 3.79 | 4.24 | 4.02 | 4.09 | 4.30 | 4.23 | 4.37 | 4.92 | 5.33 | 6.26 | 6.32 | 7.36 | 5.58 | 3.73 | 1.20 | 2.25 | 6.52 |
| R&D Expense | 111.00M | 113.00M | 118.00M | 115.00M | 121.00M | 130.00M | 125.00M | 136.00M | 141.00M | 135.00M | 132.00M | 136.00M | 145.00M | 149.00M | 132.00M | 138.00M | 126.00M | 121.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2007 | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 4.58B | 4.55B | 4.16B | 4.36B | 4.30B | 4.25B | 4.15B | 4.51B | 4.57B | 5.06B | 5.12B | 6.21B | 6.33B | 6.16B | 5.95B | 5.75B | 5.56B |
| Total Equity | 171.00M | -370.00M | -175.00M | 83.00M | -86.00M | -135.00M | 146.00M | 154.00M | 118.00M | 297.00M | 542.00M | 726.00M | 559.00M | 908.00M | 411.00M | 556.00M | 220.00M | 328.00M | 321.00M |
| Cash & Equivalents | 182.00M | 214.00M | 206.00M | 87.00M | 259.00M | 267.00M | 299.00M | 329.00M | 382.00M | 401.00M | 418.00M | 131.00M | 111.00M | 871.00M | 319.00M | 183.00M | 367.00M | 202.00M | 167.00M |
| Long Term Debt | - | - | 2.15B | 2.12B | 2.12B | 1.57B | 2.16B | 1.59B | 1.79B | 1.79B | 1.39B | 2.28B | 2.29B | 2.78B | 2.48B | 2.47B | 2.48B | 2.48B | 2.48B |
| Total Liabilities | - | - | 4.75B | 4.46B | 4.25B | 4.49B | 4.17B | 4.10B | 4.05B | 4.21B | 4.03B | 4.33B | 4.56B | 5.30B | 5.74B | 5.43B | 5.56B | 5.26B | 5.08B |
| Current Liabilities | - | - | 1.94B | 1.65B | 1.36B | 2.06B | 1.13B | 1.64B | 1.41B | 1.56B | 1.81B | 1.20B | 1.44B | 1.42B | 2.06B | 1.78B | 1.92B | 1.57B | 1.92B |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 730.00M | 738.00M | 819.00M | 698.00M | 612.00M | 775.00M | 767.00M | 874.00M | 778.00M | 865.00M | 976.00M | 992.00M | 1.55B | 1.28B | 786.00M | 1.16B | 695.00M | 981.00M |
| Investing Cash Flow | -1.08B | -197.00M | -231.00M | 544.00M | -277.00M | -55.00M | -138.00M | -106.00M | -430.00M | -205.00M | -859.00M | -196.00M | -252.00M | -452.00M | -229.00M | -223.00M | -175.00M | -94.00M |
| Financing Cash Flow | 380.00M | -540.00M | -706.00M | -1.08B | -321.00M | -685.00M | -592.00M | -696.00M | -316.00M | -645.00M | -399.00M | -815.00M | -523.00M | -1.39B | -689.00M | -753.00M | -655.00M | -924.00M |
| Capital Expenditure | -170.00M | -196.00M | -201.00M | -228.00M | -192.00M | -190.00M | -137.00M | -125.00M | -172.00M | -231.00M | -194.00M | -206.00M | -254.00M | -331.00M | -251.00M | -228.00M | -212.00M | -220.00M |
| Free Cash Flow | 560.00M | 542.00M | 618.00M | 470.00M | 420.00M | 585.00M | 630.00M | 749.00M | 606.00M | 634.00M | 782.00M | 786.00M | 1.29B | 945.00M | 535.00M | 930.00M | 483.00M | 761.00M |
| Share Buybacks | 868.00M | - | 150.00M | 655.00M | 225.00M | 128.00M | 260.00M | 434.00M | 254.00M | 183.00M | 271.00M | 661.00M | 248.00M | 905.00M | 25.00M | 0 | 0 | 332.00M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.2% | 42.7% | 44.3% | 43.5% | 42.1% | 42.5% | 42.7% | 43.6% | 45.1% | 44.7% | 43.7% | 43.9% | 45.6% | 43.6% | 35.8% | 39.4% | 43.0% | 45.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | 8.7% | 10.4% | 11.5% | 10.6% | 9.9% | 10.2% | 10.1% | 10.3% | 11.2% | 11.7% | 13.4% | 13.2% | 14.0% | 9.7% | 6.5% | 2.0% | 3.9% | 11.4% |
| ROE % | -124.6% | -306.9% | 726.5% | -647.7% | -400.7% | 391.8% | 362.3% | 491.5% | 218.2% | 129.3% | 113.4% | 146.7% | 103.4% | 172.7% | 83.1% | 67.7% | 85.4% | 252.3% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.31% | 10.04M | $1.03B |
| 2 | State Street Corporation | 6.97% | 8.43M | $864.59M |
| 3 | Vanguard Capital Management LLC | 6.53% | 7.90M | $809.62M |
| 4 | Invesco Ltd. | 4.97% | 6.01M | $616.21M |
| 5 | Vanguard Portfolio Management LLC | 4.80% | 5.80M | $594.67M |
| 6 | Geode Capital Management, LLC | 2.70% | 3.27M | $334.82M |
| 7 | Van Eck Associates Corporation | 2.46% | 2.97M | $304.82M |
| 8 | Morgan Stanley | 1.86% | 2.25M | $230.37M |
| 9 | Millennium Management Llc | 1.71% | 2.07M | $212.55M |
| 10 | UBS Group AG | 1.64% | 1.98M | $203.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLX
Nykredit A S Buys Shares of 34,360 The Clorox Company $CLX - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQck1YZUFza2lfMEcyMVFBSmIzM3kzTUt5eW5RMnlKYzlxNHRHaXZBWjVPcy1ZaE9HTTEtQWZOeFNUZHA2SWhBckptZDhxTm1VSGpiMnBUSEtZLVNRQTl2RDdpV3pmTXphSzhXSkVjcnJMajhUY21VOU9PbHh3QWZ4TTJ4SXh2YzN6UEZSX1…
Clorox (CLX) Stock Price Masks Margin Squeeze And Dividend Strain - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQczRPcjBwOFNUUmVodHU0Q0lhZUxyMm05THdGTVV0MEZVQXdfSm10T0ZUdzM1RElkNkNoanFQYUlQZVhtaE1TQlFiZEQwUnU5QjItREwzdmoyYjFkRGl3U2NEcXBOTFdNMnpTZTRTLUJwdHJ1LUlCanpLNDZDVmZxVF83SWlDWmNGdlBEYn…
Clorox (CLX) Stock May Be 32% Undervalued Despite Margin Risks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPeU9MMUJXbE9VcndwYWFxT0dpd2JtejJwa0QtenpwaWxDSnNWTFktOHlBTGNKcFlfRWRqdGxQSnIxV2pkX2VMUUt1bEJRS1VZU3hQWGhjek1sdFZiclQ4NVhBRnFuNkdRUG1DSmE1T2dWSDZKaXpoaEVYeFFxZ21jNUlvT3Atb3R6SU40R2…
Clorox Stock Extends A 6-Day Losing Streak To An 11% Loss - Trefis
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOeWg3cUY4YXdoZFJ3WTQ4OXBBTkFCenk5THJ4VUJDbnlLYWJQR2xVbnozeC1MS3RCUDNhdUJLdk1CVDhVdFRSRE1EdnM4bS16dXFGakF2c2hPaWROQWVabEVFNmxXNi1hanI0VnlGcHloek4yMDB3N2FfUmxNUWlaVUxuUUFHdy1iR2dQX3…
Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNNGpUczJKRUFnVVByUVZJMDZ6TUtZTTR6Qi1VMDhqMlgwZ0FibVpYNEo1eGYyck5UZG5IY1ZmajBZS3Y1TDNJNnl3WXNEUmdRaHVVbUNBRzNQbE12VmV6elNnU2J4SkVFcVVrUjNkaUlzYzBQbGNsenQtdm9Xejd2blkwV2RRWUdHaWw4V0…
Clorox Stock 6-Day Losing Spree: Stock Falls 11% - Trefis
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOWUtKcmJWcElGTy0xWm05Y1VxSUF4WW1Da3ZzeEJXQ2dBb09OQlMxT0FoZUNLaFpBNHp5aDNDbWg3QlhyVTRxa1M5bXZqamZKVWp5OTJKTUhjaEpWYjBWTnhRUHM1MHJLR0lESFBVZlZkQjhYR1JmRDdnajgyRkpqNFpjR1Q4dHJmdTNPcE…
CLX — Frequently Asked Questions
What is the current share price of The Clorox Company (CLX)?
As of 2026-09-07 16:24 PDT, The Clorox Company (CLX) trades at $93.06 on NYSE. Its 52-week range is $85.13 to $124.13.
What is the market capitalisation of CLX?
The Clorox Company (CLX) has a market capitalisation of $11.25B on NYSE.
What is the P/E ratio of CLX?
CLX trades at a trailing price-to-earnings (P/E) ratio of 19.39. The industry average P/E is 18.74. Its price-to-book (P/B) ratio is 141.90.
Does CLX pay a dividend?
The Clorox Company (CLX) currently offers a dividend yield of 4.73%.
Is CLX a good stock to buy?
This page provides a data-driven analysis of The Clorox Company (CLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.